The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEkf Diagnostics Regulatory News (EKF)

Share Price Information for Ekf Diagnostics (EKF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 30.00
Bid: 30.00
Ask: 30.60
Change: 0.65 (2.19%)
Spread: 0.60 (2.00%)
Open: 30.70
High: 30.70
Low: 30.00
Prev. Close: 29.65
EKF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

28 Jun 2023 07:00

RNS Number : 1143E
EKF Diagnostics Holdings PLC
28 June 2023
 

This announcement contains inside informationfor the purposes of UK Market Abuse Regulation.

 

EKF Diagnostics Holdings plc

("EKF" or the "Company")

 

Directorate Change

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, announces that Marc Davies is standing down from his role as Chief Financial Officer ("CFO") to pursue other opportunities. Marc will remain in his position to facilitate an orderly handover to his replacement for up to six months, as required.

 

The Company is already in advanced discussions with a suitable candidate for the CFO role, who is experienced in working with AIM-quoted healthcare companies, and is be able to commence the handover process within the next few weeks, with a view to taking on the role permanently in Q4 2023. A further announcement relating to this appointment will be made in due course.

 

Julian Baines remains Executive Chair and is committed to executing the Company's growth strategy, whilst also overseeing the recruitment process for a new Chief Executive Officer. An experienced senior management team continues to support the Executive Chair on an operational level, alongside significant strategic input from the Non-executive Directors.

 

Julian Baines, Executive Chair of EKF, commented: "I would like to thank Marc for his contribution to the Company. We remain confident in the financial condition and robustness of our business and the potential value that EKF offers to shareholders. We have a well-established and growing core business in Point-of Care, and an exciting opportunity in our Life Sciences division over the coming years."

 

The Company expects to give its next scheduled update on H1 trading in late July.

 

 

EKF Diagnostics Holdings plc

www.ekfdiagnostics.com

Julian Baines, Executive Chair

 Tel: +44 (0)29 2071 0570

Singer Capital Markets (Nominated Adviser & Broker)

Tel: +44 (0)20 7496 3000

Aubrey Powell / George Tzimas / Oliver Platts

Walbrook PR Limited

Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com

Paul McManus / Lianne Applegarth

Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

 

EKF is an AIM-listed global diagnostics business focussed on:

 

· Point-of-Care analysers in the key areas of Hematology and Diabetes, as well as Central Laboratory products including clinical chemistry reagents, analysers and centrifuges

 

· Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications, as well as other higher value Contract Manufacturing services

 

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAPPUUCQUPWGRM
Date   Source Headline
30th Mar 20217:01 amRNSFinal Results
30th Mar 20217:00 amRNSTrading update & Expansion of supply agreement
10th Mar 202111:45 amRNSExecutive Performance Bonus
3rd Mar 20217:00 amRNSNotice of Results
19th Feb 20214:36 pmRNSPrice Monitoring Extension
22nd Jan 20214:41 pmRNSSecond Price Monitoring Extn
22nd Jan 20214:36 pmRNSPrice Monitoring Extension
12th Jan 20217:00 amRNSTrading Update
5th Jan 20213:37 pmRNSHolding(s) in Company
30th Dec 20205:56 pmRNSHolding(s) in Company
14th Dec 20207:00 amRNSApproval of dividend in specie
10th Dec 20201:09 pmRNSResult of General Meeting
2nd Dec 20207:00 amRNSGenomic testing service launch and Change of name
26th Nov 20207:01 amRNSHolding(s) in Company
26th Nov 20207:00 amRNSCOVID-SeroKlir - FDA Emergency Use Authorisation
26th Nov 20207:00 amRNSSale of shares in Renalytix AI plc
24th Nov 20207:00 amRNSUpdate on strategic investment in Trellus Health
9th Nov 20207:00 amRNSTrading update
28th Oct 20202:15 pmRNSRe-issued: EKF marketing & distribution agreement
28th Oct 20207:00 amRNSEKF & Kantaro partner to market antibody testing
26th Oct 20207:00 amRNSDividend confirmation
22nd Oct 20207:00 amRNSNew orders for COVID-19 sample collection kits
2nd Oct 20207:00 amRNSTrading update
1st Oct 20207:00 amRNSExercise of Options and Total Voting Rights
14th Sep 20206:14 pmRNSDividend Timetable Amendment
14th Sep 20207:00 amRNSHalf-year Report
10th Sep 202012:00 pmRNSNotice of Results
20th Aug 20207:00 amRNSStrategic investment
5th Aug 20207:01 amRNSExecutive Performance Bonus
5th Aug 20207:00 amRNSSupply contract for COVID19 sample collection kits
14th Jul 20207:00 amRNSUpdate on trading and COVID-19 related contract
24th Jun 20204:40 pmRNSSecond Price Monitoring Extn
24th Jun 20204:35 pmRNSPrice Monitoring Extension
12th Jun 20204:41 pmRNSSecond Price Monitoring Extn
12th Jun 20204:35 pmRNSPrice Monitoring Extension
10th Jun 20205:43 pmRNSResults of AGM
8th Jun 20204:41 pmRNSSecond Price Monitoring Extn
8th Jun 20204:36 pmRNSPrice Monitoring Extension
15th May 20207:00 amRNSUpdate on trading and COVID-19 related contract
7th May 20207:00 amRNSPosting of Annual Report & Accounts &Notice of AGM
6th May 202011:30 amRNSExercise of options and Total Voting Rights
5th May 20204:41 pmRNSSecond Price Monitoring Extn
5th May 20204:36 pmRNSPrice Monitoring Extension
5th May 20207:00 amRNSDistribution Agreement for Quo-Test HbA1c Analyzer
29th Apr 20207:00 amRNSUK contract for COVID-19 sample collection kits
28th Apr 20207:00 amRNSCOVID-19 related manufacturing capacity update
27th Apr 20207:00 amRNSUpdate on COVID-19 related manufacturing contract
7th Apr 20207:00 amRNSFinal Results
24th Mar 20207:00 amRNSDetailed trading review including COVID-19 update
20th Mar 20207:00 amRNSInvestor results briefing update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.